| Acquired by | Shire |
| Price | $565M |
| Date | 8/10 |
| Website | movetis.com |
| Category | BioTech |
| Phone | 32 1 440 43 90 |
| Employees | |
| Founded | 2006 |
| Description | Pharmaceutical Developer |
| TOTAL | $191M |
| FUNDING TOTAL | $191M |
| Series A, 1/07 Sofinnova Partners Life Sciences Partners Sofinnova Ventures KBC Private Equity Gimv Quest for Growth BIP Investment Partners | €49M |
| Venture Round, 12/09 Credit Suisse | $128M |
Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company’s lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient’s refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.
